The true cost of vaccine protectionism - #TheAgenda with Stephen Cole
The Agenda • 1m 21s
The Agenda's Stephen Cole is joined by Pieter Cleppe, Editor-in-chief of Brussels Report and Professor Lawrence Young, virologist & specialist in molecular oncology at the University of Warwick to discuss the potential pitfalls of prioritising competition over cooperation in the distribution of COVID-19 vaccines.
France and Germany have both witnessed vaccine hesitation within their populations. We ask Pieter Cleppe, Editor-in-chief of Brussels Report, about why that might be, as well as whether Brexit is to blame for a seemingly cold reception towards the UK’s AstraZeneca jab.
How do the EU and UK vaccine rollout strategies compare? Are there more concerns about the UK-made AstraZeneca jab than other COVID-19 vaccines? And how damaging is vaccine nationalism? We find out from Professor Lawrence Young, virologist & specialist in molecular oncology at the University of Warwick.
Watch #TheAgenda in full and find out more at: https://www.cgtn.com/europe/the-agenda 📲
Follow CGTN Europe on social media and other platforms👇🏼
https://stories.cgtneurope.tv/follow-cgtn-europe/index.html
Up Next in The Agenda
-
The Vaccine Rift - #TheAgenda with St...
Questions over efficacy, blood-clot fears, threats to block exports and sluggish supply - the distribution of vaccines has been causing major division across Europe, particularly between the EU and the UK. The European Commission President Ursula von der Leyen has said AstraZeneca must honour its...
-
Productivity in numbers: Working toge...
WHAT’S THE ISSUE?
Of course as well as working from home or working from an office, there is a third option – the flexible co-working space.
Proponents of these spaces say they could be the perfect bridge between home and office work – allowing for geographical flexibility whilst enabling work...
-
Home Vs Office: Bridging the work div...
WHAT’S THE ISSUE?
Studies have shown that more than 90 percent of people currently working from home during the pandemic are keen to continue to do so at least some of the time when it ends.
But if that’s to work there are issues which both employers and employees are going to have to solve, mo...
